About This Study Log

The purpose

AgeDefy Peptide gathers and plainly restates the published research on two molecules studied for longevity and cellular health: NAD+ (nicotinamide adenine dinucleotide) and MOTS-c, the peptide the mitochondrion encodes within its 12S rRNA gene. The aim is to make a scattered, unevenly reported, and often overhyped body of work readable — to say, in ordinary language and with a citation attached, what each molecule was actually tested for, in which species, and how far that evidence honestly stretches.

Two vantage points on cellular aging hold the site together: the coenzyme that fuels and tunes the cell (NAD+) and the stress-and-aging signal the mitochondrion sends out on its own (MOTS-c). Both have been probed in age-related metabolic decline and longevity biology, and both show the field's recurring hard problem — carrying striking preclinical and mechanistic data across the gap into proven human outcomes. Each molecule keeps its own page, a comparison page sets them beside each other, and one shared list collects every source.

Three ground rules

Three ground rules decide what lands on the site.

The literature comes first. Every research statement carries a numbered citation — PubMed-indexed articles and reviews, with DOIs or PubMed links — assembled on the references page. When a claim traces to a review rather than a primary study, it is cited as a review.

Evidence is quoted at the strength it actually has. Doses appear in the species and route where they were studied — say, "given at 0.5-15 mg/kg/day in mice" — and are never rescaled to people or dressed up as a suggestion. Where the support is preclinical, observational, or leans on a proxy marker such as a rise in blood NAD+ instead of a hard clinical endpoint, the page admits it. That frankness about the edges of the data is the whole reason the site exists.

The pages talk to each other. Since mitochondrial function, AMPK signaling, cellular energy, and age-related metabolic decline surface across both molecules, the entries link among themselves and to the comparison page, so a reader can trace one mechanism across the whole terrain.

Where the site stops

AgeDefy Peptide is no storefront, no clinic, and no substitute for a doctor. It trades in nothing — no research compound, no supplement, no IV therapy changes hands here, and no affiliate or referral deal ties it to any seller. There are no prescribers on staff, no diagnoses offered, and no dose, schedule, or route named for anyone; an animal-study amount is never dressed up as a human plan.

The two molecules sit in different regulatory boxes: NAD+ precursors are sold widely as supplements and dripped as compounded IV therapy, while MOTS-c is a research chemical meant for the bench. Neither is an approved treatment for age-related conditions, and MOTS-c is flatly banned in sport. A reader weighing any condition named in the underlying research should take it to a licensed clinician in their own jurisdiction, working from regulated, evidence-based options. What the site provides is a steady, accurate map of the published record — and nothing it isn't.